Preoperative Hemoglobin and Outcomes in Patients with CKD Undergoing Cardiac Surgery
|
|
- Austin Campbell
- 5 years ago
- Views:
Transcription
1 CJASN epress. Published on July 3, 2014 as doi: /CJN Article Preoperative Hemoglobin and Outcomes in Patients with CKD Undergoing Cardiac Surgery Linda Shavit,* Sharbel Hitti, Shuli Silberman, Rachel Tauber, Ofer Merin, Meyer Lifschitz,* Itzchak Slotki,* Daniel Bitran, and Daniel Fink Abstract Background and objectives Preoperative anemia adversely affects outcomes of cardiothoracic surgery. However, in patients with CKD, treating anemia to a target of normal hemoglobin has been associated with increased risk of adverse cardiac and cerebrovascular events. We investigated the association between preoperative hemoglobin and outcomes of cardiac surgery in patients with CKD and assessed whether there was a level of preoperative hemoglobin below which the incidence of adverse surgical outcomes increases. Design, setting, participants, & measurements This prospective observational study included adult patients with CKD stages 3 5(eGFR,60 ml/min per 1.73 m 2 ) undergoing cardiac surgery from February 2000 to January Patients were classified into four groups stratified by preoperative hemoglobin level:,10, , , and $14 g/dl. The outcomes were postoperative AKI requiring dialysis, sepsis, cerebrovascular accident, and mortality. Results In total, 788 patients with a mean egfr of ml/min per 1.73 m 2 were evaluated, of whom 22.5% had preoperative hemoglobin within the normal range (men: g/dl; women: g/dl). Univariate analysis revealed an inverse relationship between the incidence of all adverse postoperative outcomes and hemoglobin level. Using hemoglobin as a continuous variable, multivariate logistic regression analysis showed a proportionally greater frequency of all adverse postoperative outcomes per 1-g/dl decrement of preoperative hemoglobin (mortality: odds ratio, 1.38; 95% confidence interval, 1.23 to 1.57; P,0.001; sepsis: odds ratio, 1.31; 95% confidence interval, 1.14 to 1.49; P,0.001; cerebrovascular accident: odds ratio, 1.31; 95% confidence interval, 1.00 to 1.67; P=0.03; postoperative hemodialysis: odds ratio, 1.38; 95% confidence interval, 1.11 to 1.75; P,0.01). Moreover, preoperative hemoglobin,12 g/dl was an independent risk factor for postoperative mortality (odds ratio, 2.6; 95% confidence interval, 1.1 to 7.3; P=0.04). *Adult Nephrology Unit and Department of Cardiac Surgery, Shaare Zedek Medical Center, Jerusalem, Israel Correspondence: Dr. Linda Shavit, Adult Nephrology Unit, Shaare Zedek Medical Center, PO Box 3235, Jerusalem 91031, Israel. lshavit@ szmc.org.il Conclusions Similar to the general population, preoperative anemia is associated with adverse postoperative outcomes in patients with CKD. Whether outcomes could be improved by therapeutically targeting higher preoperative hemoglobin levels before cardiac surgery in patients with underlying CKD remains to be determined. Clin J Am Soc Nephrol 9: ccc ccc, doi: /CJN Introduction Anemia is a common complication of CKD, and it is associated with adverse clinical outcomes and poor health related quality of life (1 3). Surprisingly, normalization of hemoglobin in patients with CKD has not been associated with clear clinical benefits. Recently, several large randomized controlled trials testing the effect of using erythropoietin-stimulating agents (ESAs) to achieve various hemoglobin targets have shown that high hemoglobin target levels are associated with higher rates of adverse outcomes, including cardiovascular mortality, cerebrovascular events, and vascular access thrombosis (4 6). Therefore, the US Food and Drug Administration (FDA) recommends targeting the lowest hemoglobin that will prevent blood transfusion in patients with CKD, and the newest Kidney Disease Improving Global Outcomes and European guidelines state that ESAs should not be used to maintain hemoglobin concentrations.11.5 g/dl (7,8). At the present time, patients with CKD and ESRD die primarily because of cardiovascular events, and a substantial percentage of these patients will require cardiothoracic surgery during their lifespan (9,10). By following the current FDA and European recommendations, most of these patients with CKD will be anemic before surgery. Is the target hemoglobin between g/dl optimal for these patients before such a stressful intervention? What is the preoperative hemoglobin that will be associated with the lowest incidence of adverse surgical outcomes in the CKD population? On thebasisofcurrentevidenceweknowthat,inthe general population, preoperative anemia adversely affects the outcomes of cardiothoracic surgery (11 16). Vol 9 September, 2014 Copyright 2014 by the American Society of Nephrology 1
2 2 Clinical Journal of the American Society of Nephrology However, in the growing population of patients with CKD, the optimal preoperative hemoglobin targets have not previously been explored. This subject has become especially relevant in light of new and relatively strict FDA recommendations, at least in ESA-treated patients with CKD, and the fact that preoperative hemoglobin is, potentially, a simply modifiable risk factor. The aims of this study were to (1) determine whether preoperative hemoglobin independently influences outcomes of cardiac surgery in patients with CKD and (2) define an optimum level of preoperative hemoglobin that is associated with the lowest incidence of adverse surgical outcomes in the CKD population undergoing cardiac surgery. Materials and Methods Study Population and Data Collection This observational study included adult patients with CKD stages 3 5 (egfr,60 ml/min per 1.73 m 2 ) undergoingcardiacsurgeryfromfebruaryof2000tojanuaryof 2010 at Shaare Zedek Medical Center, Jerusalem, Israel. All data were collected prospectively on a daily basis by research assistants who completed preoperative, intraoperative, and postoperative datasheets. The preoperative and intraoperative datasheets contain demographic data, variables related to the severity of disease, comorbid factors before surgery, and operative features. The postoperative datasheet contains variables related to in-hospital outcomes after surgery. The same research assistant, who was blinded to the patients preoperative hemoglobin levels, determined all postoperative outcomes according to standard definitions. Eligible patients included individuals 18 years of age or older with CKD stages 3 5 (on the basis of the National Kidney Foundation CKD classification: stage 3, egfr=30 59 ml/min per 1.73 m 2 ; stage 4, egfr=15 29 ml/min per 1.73 m 2 ; stage 5, egfr,15 ml/min per 1.73 m 2 ) undergoingcardiacsurgeryfromfebruaryof2000tojanuaryof 2010 in our center either electively or urgently. Patients on chronic dialysis were excluded. Written consent was not obtained from the individual patients, because the study is on the basis of data collected for routine care. Local ethics committee approval was obtained. Study Methods Patients were classified into four groups stratified by preoperative hemoglobin level,10, , , and $14 g/dl (referred to as normal preoperative hemoglobin). The reference range for hemoglobin in our laboratory is g/dl in men and g/dl in women. Preoperative egfr was estimated in all patients by the four-component Modification of Diet in Renal Disease equation on the basis of preoperative creatinine levels (reference range= mg/dl; isotope dilution mass spectrometry traceable). In addition, to ensure the chronic stable nature of the kidney disease, in-hospital creatinine measurements during the preoperative period were compared with values obtained from either the family physician s referral letter or previous in-hospital medical records. The following preoperative patient-related characteristics were recorded: age, sex, medical history of heart failure (according to New York Heart Association [NYHA] classification), left main coronary artery disease, diabetes mellitus (DM), hypertension, hyperlipidemia, peripheral vascular disease (PVD), cerebrovascular accident (CVA), and chronic obstructive pulmonary disease. Operative features included type of operation performed (coronary artery bypass graft [CABG], valvular or combined), incidence and indications for intra-aortic balloon pump use, surgery status (elective, emergent, emergent/salvage, and urgent), perfusion time, crossclamp time, and use of off-pump surgery. Postoperative complications recorded included AKI defined by RIFLE criteria (risk, injury, and failure stages), infections, prolonged mechanical ventilation (.24 hours),cva,myocardial infarction, acute respiratory distress syndrome, in-hospital mortality incidence and causes, intensive care unit stay, and hospital stay. Outcomes The outcomes studied were postoperative AKI requiring dialysis, in-hospital mortality (regardless of length of stay), and major morbidities, including neurologic (CVA) and infectious (septic shock or other infections) morbidities requiring intravenous antibiotics. Statistical Analyses Analysis was performed using JMP Software, version 5.0 (SAS Institute). Data are expressed as mean6sd, except for parameters not normally distributed, which are shown as median (25th, 75th percentile). The association of potential risk factors with operative mortality or morbidity was assessed by univariate analysis; nominal and categorical variables were compared using the chi-squared likelihood ratio or Fisher exact test. Continuous variables were compared using the nonparametric Wilcoxon test. Factors with P value #0.05 in the univariate analysis were included in a stepwise multivariate logistic regression analysis. The criterion for entering factors into the stepwise regression model was a P value=0.25 to expose variables that were not related to the outcome but could be confounders. In the multivariate analysis, we used logistic regression analysis to determine the association between preoperative hemoglobin as a continuous variable and complications as dichotomous variables. We calculated the odds ratio (OR) for each 1-g/dl decrement of the preoperative hemoglobin in the logistic regression analysis. To find the cutoff values of preoperative hemoglobin potentially associated with adverse clinical outcomes, patients were divided into groups on the basis of their preoperative hemoglobin. Bar charts of ORs and P values were obtained through comparison of the selected group with the group with normal preoperative hemoglobin ($14). Differences are reported as significant if P value is,0.05. Results During a 10-year period, 788 patients with preoperative CKD stages 3 5 underwent cardiac surgery. Tables 1 and 2 represent the baseline patient- and procedure-related characteristics of the whole study population and patients stratified by preoperative hemoglobin levels. The average age of the study population was years; 60% of them were men. Mean plasma creatinine concentration was mg/dl (range= ), and mean egfr was ml/min per 1.73 m 2 (range= ). A high incidence of preoperative comorbidities was observed: severe
3 Clin J Am Soc Nephrol 9: ccc ccc, September, 2014 Anemia in CKD Patients Undergoing Cardiac Surgery, Shavit et al. 3 Table 1. Patient-related characteristics stratified by preoperative hemoglobin levels Patient-related Characteristics All Patients (n=788) Hb,10 (n=73) Patient, N Hb= (n=210) Hb= (n=325) Hb$14 (n=180) P Value Sex (men) 481 (60%) 40 (55%) 105 (50%) 184 (57%) 148 (82%),0.001 Age, yr (26 91) Preoperative ( ) ,0.001 creatinine, mg/dl egfr, ml/min ( ) ,0.001 per 1.73 m 2 CHF NYHA classification I 115 (16%) 4 (5%) 16 (8%) 54 (17%) 39 (22%),0.001 II 99 (13%) 3 (4%) 23 (11%) 44 (13%) 27 (15%) 0.06 III 267 (36%) 24 (33%) 67 (32%) 114 (35%) 58 (32%) 0.86 IV 259 (35%) 38 (52%) 91 (43%) 83 (25%) 43 (24%),0.001 Left main art..50% 115 (14%) 9 (12%) 29 (14%) 52 (16%) 24 (13%) 0.77 PVD 117(15%) 16 (22%) 34 (16%) 46 (14%) 20 (11%) 0.15 Hyperlipidemia 554 (70%) 48 (66%) 151 (72%) 219 (67%) 127 (70%) 0.62 HTN 645 (81%) 63 (86%) 179 (85%) 256 (79%) 139 (77%) 0.08 DM 334 (42%) 48 (66%) 108 (51%) 124 (38%) 48 (27%),0.001 CVA 93 (12%) 11 (15%) 28 (13%) 35 (11%) 18 (10%) 0.55 COPD 94 (12%) 11 (15%) 24 (11%) 41 (13%) 16 (9%) 0.47 Medications, n (%) Diuretics 389 (57%) 34 (62%) 126 (68%) 159 (55%) 70 (45%),0.001 ACE inhibitors 368 (54%) 31 (56%) 107 (58%) 152 (53%) 78 (50%) 0.58 ARBs 81 (12%) 8 (15%) 24 (13%) 36 (13%) 13 (8%) 0.45 Statins 381 (56%) 32 (58%) 106 (57%) 150 (52%) 93 (60%) 0.46 Aspirin 496 (63%) 41 (56%) 123 (59%) 208 (64%) 124 (69%) 0.11 Ca channels 147 (19%) 11 (15%) 46 (22%) 61 (19%) 29 (16%) 0.41 blockers b-blockers 455 (58%) 36 (49%) 123 (59%) 200 (62%) 96 (53%) 0.14 CHF, congestive heart failure; NYHA, New York Heart Association; art, artery; PVD, peripheral vascular disease; HTN, hypertension; DM, diabetes mellitus; CVA, cerebrovascular accident; COPD, chronic obstructive pulmonary disease; ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor antagonists; Ca, calcium; Hb, hemoglobin heart failure (NYHA classification IV), 35%; DM, 42%; hypertension, 81%; hyperlipidemia, 70%; CVA, 12% (Table 1). In total, 37% of patients underwent CABG, 25% of patients had valvular surgery, and the remaining patients had a combinationofboth(table2). After stratification by preoperative hemoglobin, four groups of patients were created. There were 73 patients in the first group (hemoglobin,10 g/dl), 210 patients in the second group (hemoglobin= g/dl), 325 patients in the third group (hemoglobin= g/dl), and 180 patients in the fourth group (hemoglobin$14 g/dl). Lower preoperative hemoglobin was associated with higher prevalence of DM, severe heart failure (NYHA classification IV), advanced preoperative CKD, use of diuretics, higher incidence of perioperative (intraoperative and postoperative) blood transfusions, and prolonged crossclamp and perfusion times (Tables 1 and 2). In total, 636 patients received blood transfusions, and the incidence was significantly higher in patients with preoperative hemoglobin,14 g/dl (P,0.001). However, there were no statistically significant differences among groups in a number of important preoperative and intraoperative variables. Patients were similar in age; prevalence of chronic obstructive pulmonary disease, PVD, hypertension, hyperlipidemia, and CVA; preoperative medication use, including angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, statins, aspirin, and b-blockers; incidence of valvular and CABG and valve operations; surgery status (elective, urgent, emergent, or emergent/salvage operations); and hemodynamic instability requiring intra-aortic balloon pump. Not unexpectedly, 82% of patients with hemoglobin.14 g/dl were men compared with about 50% of patients in other hemoglobin groups (P,0.001). Overall, 26.6% of patients reached the study outcomes: 23 (2.8%) patients developed postoperative AKI requiring dialysis, 20 (2.5%) patients had a CVA, 74 (9.2%) patients had postoperative sepsis, and 96 (12%) patients died during the hospitalization. Figure 1 shows the unadjusted analysis of the incidence of adverse postoperative outcomes in groups of patients stratified by preoperative hemoglobin. A clear inverse association between the incidence of all four outcomes and preoperative hemoglobin values was detected. Only nine (1%) patients developed postoperative myocardial infarction: four (2%), one (0.3%), two (1%), and two (3%) patients with preoperative hemoglobin of $14, , , and,10 g/dl, respectively (P=0.10).
4 4 Clinical Journal of the American Society of Nephrology Table 2. Procedure-related characteristics stratified by preoperative hemoglobin levels Procedure Characteristics All Patients (n=788) Hb,10 (n=73) Hb= (n=210) Hb= (n=325) Hb$14 (n=180) P Value Type of procedure CABG 295 (37%) 13 (18%) 58 (28%) 128 (39%) 94 (52%),0.001 CABG and valve 180 (22%) 17 (23%) 54 (26%) 71 (21%) 23 (13%) 0.23 Valvular surgery 185 (22%) 22 (30%) 52 (25%) 69 (22%) 38 (21%) 0.33 Other 140 (17%) 21 (29%) 46 (21%) 57 (18%) 25 (16%) 0.58 Surgery status Elective 604 (75%) 54 (74%) 165 (79%) 237 (73%) 138 (77%) 0.48 Emergent 45 (6%) 5 (7%) 11 (5%) 20 (6%) 7 (4%) 0.68 Emergent/salvage 20 (3%) 0 3 (1%) 9 (3%) 8 (4%) 0.13 Urgent 131 (16%) 14 (19%) 31 (15%) 59 (18%) 27 (15%) 0.62 IABP incidence 66 (8%) 6 (8%) 19 (9%) 23 (7%) 16 (9%) 0.83 Crossclamp time 25th Percentile Median th Percentile Perfusion time 25th Percentile ,0.001 Median th Percentile Inotrope use 245 (31%) 31 (42%) 74 (35%) 95 (29%) 45 (25%) 0.02 Perioperative blood transfusion 636 (81%) 68 (93%) 194 (92%) 267 (82%) 107 (59%),0.001 Crossclamp and perfusion times, which were not normally distributed, are given as medians, 25th percentiles, and 75th percentiles. CABG, coronary artery bypass graft; IABP, intra-aoritc balloon pump; Hb, hemoglobin. Figure 1. Inverse relationship between preoperative hemoglobin and a frequency of postoperative adverse outcomes was detected by univariate analysis. Incidence of postoperative AKI requiring dialysis, sepsis, cerebrovascular accident (CVA), and mortality according to preoperative hemoglobin (Hb) as detected by univariate analysis. For each outcome, bars are (from left to right) Hb,10, , , and $14 g/dl. Postoperative AKI requiring dialysis was also inversely related to preoperative hemoglobin: 1%, 2%, 3%, and 10% (P=0.01 for trend) in patients with preoperative hemoglobin values of $14, , , and,10 g/dl, respectively. A similar relationship was seen for mortality: 4%, 11%, 14%, and 32% in the respective groups (P,0.001 for trend). Analogous trends were detected for other outcomes (P,0.001 for postoperative sepsis and P=0.01 for postoperative CVA) (Figure 1). The association between preoperative hemoglobin and postoperative AKI defined by RIFLE criteria (risk, injury, and failure stages) is presented in Table 3. Of those patients who developed AKI, 90 patients were classified as risk, 67 patients were classified as injury, and
5 Clin J Am Soc Nephrol 9: ccc ccc, September, 2014 Anemia in CKD Patients Undergoing Cardiac Surgery, Shavit et al patients were classified as failure. The incidence of all stages of AKI was inversely related to preoperative hemoglobin, and these findings were statistically significant. The incidence of failure stage, for example, was 3%, 6%, 14%, and 26% (P,0.001) in patients with preoperative hemoglobin of $14, , , and,10 g/dl, respectively. Similar trends were detected for earlier stages (P=0.03 for risk and P=0.002 for injury) (Table 3). Figure 2 shows stepwise multivariate logistic regression analysis of the association between preoperative hemoglobin as a continuous variable and the four major postoperative adverse outcomes: sepsis, postoperative dialysis, CVA, and mortality. Adjustment was performed for all identified confounders with P value #0.05 in the univariate analysis and included sex, severity of preoperative CKD (on the basis of serum creatinine and egfr), severity of preoperative heart failure (NYHA classifications I and IV), baseline DM, incidence of blood transfusion, type of surgery (CABG alone versus the combination of CABG and valve surgery), use of diuretics, intraoperative inotrope use, and crossclamp and perfusion times. It can be seen that the frequency of all adverse postoperative outcomes was inversely related to preoperative hemoglobin. For every 1-g/dl decrement of preoperative hemoglobin, there was a proportionally greater incidence of mortality (OR, 1.38; 95% confidence interval [95% CI], 1.23 to 1.57; P,0.001), sepsis (OR, 1.31; 95% CI, 1.14 to 1.49; P,0.001), CVA (OR, 1.31; 95% CI, 1 to 1.67; P=0.03), and postoperative hemodialysis (OR, 1.38; 95% CI, 1.11 to 1.75; P,0.01). No interaction by sex was detected in the above associations (P=0.90 for mortality, P=0.10 for sepsis, P=0.60 for CVA, and P=0.50 for dialysis). To determine threshold values of preoperative hemoglobin that independently predicted surgical outcomes, we calculated ORs (obtained after adjustment with the previously identified confounders) for postoperative dialysis, AKI according to RIFLE criteria, mortality, and sepsis in patients stratified by preoperative hemoglobin at cutoff points of 10, 11, 12, 13, and 14 g/dl compared with the reference group (Figure 3, Table 4). We showed that preoperative hemoglobin,12 g/dl was an independent risk factor for mortality (OR, 2.5; 95% CI, 1.1 to 7.3; P=0.04) and that preoperative hemoglobin,11 g/dl was independently associated with a higher incidence of both postoperative mortality (OR, 2.6; 95% CI, 1.1 to 5.3; P=0.04) and sepsis (OR, 3.8; 95% CI, 1.6 to 10; P=0.003). No significant association between hemoglobin and postoperative dialysis requirement was observed (OR, 1.6; 95% CI, 0.4 to 10.4; P=0.50). However, we found that preoperative hemoglobin,12 (OR, 2.7; 95% CI, 1.1 to 7.9; P=0.04) and,11 g/dl (OR, 2.6; 95% CI, 1.1 to 6.5; P=0.03) were independent risk factors for RIFLE stages failure and risk of postoperative AKI, respectively (Table 4). These associations were equally shown in both sexes. We could not calculate ORs for CVA, because there were no patients in the reference group who had a postoperative CVA. Analysis of mortality data revealed infection as the most common cause of death in patients with anemia, whereas cardiac death was the most common cause in patients with preoperative hemoglobin.14 g/dl. Discussion Our prospective cohort study showed several interesting findings related to preoperative hemoglobin in patients with significant CKD undergoing open heart surgery. First, low hemoglobin in patients with CKD is associated with increased prevalence of some but not all comorbidities. As expected, we found more severe anemia in patients with diabetes and advanced stages of heart and kidney diseases. However, anemia was not associated with age, hypertension, PVD, or preoperative CVA. Second, multivariate logistic regression analysis using hemoglobin as a continuous variable showed a remarkable and continuous inverse relationship between decreasing hemoglobin and the frequency of postoperative sepsis, CVA, AKI requiring hemodialysis, and in-hospital mortality. Third, we showed that, similar to patients without CKD, preoperative anemia in patients with CKD stages 3 5 is an independent risk factor for adverse postoperative outcomes, even after adjustment for CKD severity. Fourth, we defined threshold values of preoperative hemoglobin that were significantly and independently associated with adverse postoperative outcomes. Thus, preoperative hemoglobin,12 g/dl was an independent risk factor for postoperative failure stage of AKI and mortality, and hemoglobin,11 g/dl was independently associated with postoperative sepsis, risk, and failure stages of AKI, and higher mortality. Recently, several studies addressed preoperative anemia as a predictor of poor outcomes after cardiac surgery (11 16). Most of them showed that low hemoglobin level, as both a continuous variable and a dichotomous variable, is a predictor of higher in-hospital and late mortality. In addition, both preoperative anemia and perioperative red blood cell transfusions were independently and strongly associated with postoperative AKI, which by itself, results in a.4-fold increase in the odds of death (13). However, none of these studies was focused on or specifically designed to detect a relationship between preoperative hemoglobin and outcomes of cardiac surgery in patients with significant CKD. Anemia is common in patients with CKD, and some studies suggested that treatment with ESAs and Table 3. Association between preoperative hemoglobin and postoperative AKI as defined by RIFLE criteria AKI Stages by RIFLE Criteria Preoperative Hemoglobin, g/dl,10 (n=73) (n=210) (n=325) $14 (n=180) P Value Risk 15 (21%) 25 (12%) 37 (11%) 13 (7%) 0.03 Injury 12 (16%) 26 (12%) 20 (6%) 9 (5%) Failure 19 (26%) 29 (14%) 18 (6%) 6 (3%),0.001
6 6 Clinical Journal of the American Society of Nephrology Figure 2. Lower preoperative hemoglobin is associated with proportionally greater incidence of postoperative adverse outcomes by multivariate analysis. Stepwise multivariate logistic regression analysis of association between preoperative hemoglobin (Hb) as the continuous variable and (A) mortality, (B) sepsis, (C) CVA, and (D) postoperative dialysis. Odds ratio (OR) is calculated per each 1-g/dl decrement of preoperative Hb as a continuous variable. Adjustment was performed for all identified confounders with P value #0.05 in the univariate analysis. CI, confidence interval. intravenous iron can improve left ventricular ejection fraction, renal function, and functional capacity in patients with heart failure and anemia (17 21). Moreover, the study by Cladellas et al. (21) showed that combined therapy with intravenous erythropoietin and iron administered before valvular cardiac surgery in patients with anemia was associated with a significant improvement in postoperative outcomes and a significant decrease in need for red blood cell transfusions. However, in the study, only 14% of patients in both intervention (75 patients) and observation (59 patients) cohorts had preoperative creatinine levels.1.5 mg/dl, and egfr data were not provided (21). Recently, several randomized control trials have led to a major reassessment of anemia management in CKD: the Normal Hematocrit study in patients on hemodialysis with clinical signs of congestive heart failure or ischemic heart disease, studies from Europe (Cardiovascular Risk Reduction by Early Anemia Treatment with Epoetin-b) and the United States (Correction of Hemoglobin and Outcomes in Renal Insufficiency) in patients before dialysis, and finally, the Trial to Reduce Cardiovascular Events with Aranesp Therapy study on patients with diabetes, CKD, and anemia. These studies have provided evidence that the normalization of hemoglobin levels to g/dl in patients with CKD stages 3 or 4 does not reduce cardiovascular events compared with the use of a lower target range ( g/dl). Moreover, the use of darbepoetin alfa in patients with diabetes, CKD, and moderate anemia did not reduce the risk of either death or a cardiovascular event and was associated with an increased risk of stroke (4 6). The reasons for this finding are not entirely clear but may be caused by a combination of several factors: higher hemoglobin concentration itself, rapidity of the increase or oscillations in hemoglobin levels, overshoot of the target, or some off-target effect of ESAs, such as trophic effects on vascular endothelial or smooth-muscle cells (22). Interestingly, patients who achieved the higher hemoglobin had better outcomes, whereas a poor initial hematopoietic response to darbepoetin alfa was associated with an increased subsequent risk of death or cardiovascular events as doses were escalated to meet target hemoglobin levels (23). Regardless of pathogenetic mechanisms, clinical practice guidelines have been changed and recommend maintaining hemoglobin levels in the range of g/dl in CKD. Our study showed that, before cardiac surgery, this range of preoperative hemoglobin was independently
7 Clin J Am Soc Nephrol 9: ccc ccc, September, 2014 Anemia in CKD Patients Undergoing Cardiac Surgery, Shavit et al. 7 Figure 3. Preoperative hemoglobin levels <12g/dl and <11 g/dl represent an independent risk factors for postoperative mortality and sepsis, respectively. Adjusted OR for postoperative outcomes in patients stratified by preoperative hemoglobin (Hb) levels. Values were obtained by multivariate analysis after adjustment for all identified confounders with P value #0.05 in the univariate analysis and included sex, severity of preoperative CKD (on the basis of serum creatinine and egfr), severity of preoperative heart failure (NYHA classifications I and IV), baseline diabetes mellitus, incidence of blood transfusion, type of surgery (coronary artery bypass graft alone versus a combination of coronary artery bypass graft and valve surgery), use of diuretics, intraoperative inotrope use, and crossclamp and perfusion times. Selected groups were compared with the reference group with preoperative Hb.14 g/dl. Statistically significant values: *P=0.003; **P=0.04; ***P, NYHA, New York Heart Association. Table 4. Adjusted odd ratios for postoperative AKI defined by RIFLE criteria in patients stratified by preoperative hemoglobin levels (selected group compared with the reference group with preoperative hemoglobin>14 g/dl) AKI Stages by RIFLE Criteria Preoperative Hemoglobin, g/dl,10,11,12,13,14 Risk Odds ratio; 95% confidence 2.6; 1.1 to ; 1.1 to ; 1.0 to 5.0 2; 1.0 to 4.5 2; 1.0 to 4.7 interval P value Injury Odds ratio; 95% confidence 1.6; 1.5 to ; 1.0 to ; 1.1 to ; 1.0 to ; 1.0 to 3.0 interval P value Failure Odds ratio; 95% confidence 4.7; 1.6 to ; 1.7 to ; 1.1 to ; 1.0 to ; 1.0 to 6.1 interval P value Values were obtained by multivariate analysis after adjustment for sex, severity of preoperative CKD, severity of preoperative heart failure (NYHA classifications I and IV), baseline diabetes mellitus, incidence of blood transfusion, type of surgery (CABG alone versus a combination of CABG and valve surgery), use of diuretics, intraoperative inotrope use, and crossclamp and perfusion times. associated with a.2-fold greater risk of hospital mortality and postoperative AKI. It is not clear, however, whether the correction of preoperative hemoglobin by ESAs or blood transfusion will improve postoperative outcomes. Interestingly, the main cause of death in patients with anemia was infection, but patients with hemoglobin.14 g/dl were more likely to die from cardiovascular causes. Although anemia has been extensively shown as an independent risk factor for postoperative infection in both cardiac and noncardiac surgery (13,14,19,21,24), our study showed that patients with higher hemoglobin die mostly from cardiac complications. This fact, however, can be explained by a low rate of sepsis, sepsis-related, and overall mortality in this subgroup, leaving cardiovascular events as the leading cause of death.
8 8 Clinical Journal of the American Society of Nephrology It is not completely clear whether this finding is unique for the CKD population. In fact, our results are in line with the observation that patients with CKD with higher hemoglobin levels have increased cardiovascular mortality. Despite its complexity, a sufficiently powered randomized placebo controlled trial will be required to shed light on the phenomenon of optimal preoperative hemoglobin levels in patients with CKD undergoing cardiac surgery. Our study has some limitations. First, it was on the basis of observational data, and we cannot entirely rule out known or unknown confounding factors as an explanation for our results. However, recall bias can be excluded in our study, because data collection was uniform in all patients; the same research assistants completed preoperative, intraoperative, and postoperative datasheets prospectively on a daily basis. In addition, no changes in definitions of comorbidities or studied outcomes were performed during the whole period of the study. Second, despite multivariate analysis, a powerful influence of lower preoperative egfr by itself on postoperative morbidity and mortality in patients with greater anemia cannot be entirely ruled out. In addition, our data have been collected over a prolonged period of time, and therefore, the possibility of changes in both perioperative and surgical management strategies over these years should be considered. These strategies include myocardial preservation with crystalloid solutions containing tryptophan, histidine, and ketoglutarate instead of hyperkalemic solutions and a liberal postoperative fluid-management policy to reduce the need for inotropic and vasopressor support. Furthermore, our patient population has changed over the years, with an increase in age and other comorbidities. Despite these changes, no trend in the average Euroscore or intraoperative or postoperative characteristics could be detected between periods preceding and succeeding these major changes; also, there was no significant vintage effect on mortality or other outcomes. One of the prominent limitations of our study is that data on preoperative ESA use and dose were not consistently recorded and therefore, could not be analyzed. Thus, the role of ESAs and their potential significant influence on patient outcomes in this specific surgical setting cannot be addressed. Finally, our definition of CKD was on the basis of egfr and not measured GFR. Importantly, because of the observational design of our study, the possibility of residual confounding remains a serious limitation, and the only conclusionthatcanbedrawnisanassociationbetweenanemia and adverse postoperative outcomes. Although our study cannot show direct causality or help guide clinicians on treatment decisions, it can be considered as hypothesisgenerating and serve as an important basis for future controlled trials exploring potential benefits of therapeutically targeting higher preoperative hemoglobin levels before cardiac surgery. In summary, we evaluated a relatively large cohort of patients with CKD undergoing open heart surgery and focused specifically on the subject of preoperative hemoglobin and clinical outcomes. We showed a substantially greater risk of mortality and postoperative sepsis at threshold values of hemoglobin,12 and,11 g/dl, respectively. Although low hemoglobin levels were associated with a higher burden of comorbidities, multivariate analysis showed that anemia was an independent risk factor for adverse postoperative outcomes. Our findings raise several important questions that may have an effect on the care of patients with CKD undergoing cardiac surgery, especially in light of the easily modifiable nature of preoperative anemia. However, the role of therapeutic strategies aimed to increase preoperative hemoglobin and diminish postoperative complications in the CKD population undergoing cardiac surgery remains to be elucidated in a prospective randomized trial. Disclosures None. References 1. Barrett BJ, Fenton SS, Ferguson B, Halligan P, Langlois S, Mccready WG, Muirhead N, Weir RV; Canadian Society of Nephrology: Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. J Am Soc Nephrol 10[Suppl 13]: S292 S296, KDOQI; National Kidney Foundation: KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 47[Suppl 3]: S11 S145, Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355: , Drüeke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A; CREATE Investigators: Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 355: , Besarab A, Bolton WK, Browne JK, Egrie JC, Nissenson AR, Okamoto DM, Schwab SJ, Goodkin DA: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. NEnglJ Med 339: , Pfeffer MA, Burdmann EA, Chen CY, Cooper ME, de Zeeuw D, Eckardt KU, Feyzi JM, Ivanovich P, Kewalramani R, Levey AS, Lewis EF, McGill JB, McMurray JJ, Parfrey P, Parving HH, Remuzzi G, Singh AK, Solomon SD, Toto R; TREAT Investigators: A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. NEnglJMed361: , US Food and Drug Administration: Ongoing Safety Review Erythropoiesis-Stimulating Agents (ESAs) Epoetin Alfa (Marketed as Procrit, Epogen) and Darbepoetin Alfa (Marketed as Aranesp): Update, US Department of Health & Human Services, 2013, US Food and Drug Administration 8. KDIGO: KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2: , Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, Hiesmayr M: Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: A prospective cohort study. J Am Soc Nephrol 15: , Cooper WA, O Brien SM, Thourani VH, Guyton RA, Bridges CR, Szczech LA, Petersen R, Peterson ED: Impact of renal dysfunction on outcomes of coronary artery bypass surgery: Results from the Society of Thoracic Surgeons National Adult Cardiac Database. Circulation 113: , Ranucci M, Di Dedda U, Castelvecchio S, Menicanti L, Frigiola A, Pelissero G; Surgical and Clinical Outcome Research (SCORE) Group: Impact of preoperative anemia on outcome in adult cardiac surgery: A propensity-matched analysis. Ann Thorac Surg 94: , Karkouti K, Wijeysundera DN, Yau TM, Callum JL, Cheng DC, Crowther M, Dupuis JY, Fremes SE, Kent B, Laflamme C, Lamy A, Legare JF, Mazer CD, McCluskey SA, Rubens FD, Sawchuk C, Beattie WS: Acute kidney injury after cardiac surgery: Focus on modifiable risk factors. Circulation 119: , Karkouti K, Wijeysundera DN, Beattie WS; Reducing Bleeding in Cardiac Surgery (RBC) Investigators: Risk associated with
9 Clin J Am Soc Nephrol 9: ccc ccc, September, 2014 Anemia in CKD Patients Undergoing Cardiac Surgery, Shavit et al. 9 preoperative anemia in cardiac surgery: A multicenter cohort study. Circulation 117: , Kulier A, Levin J, Moser R, Rumpold-Seitlinger G, Tudor IC, Snyder-Ramos SA, Moehnle P, Mangano DT; Investigators of the Multicenter Study of Perioperative Ischemia Research Group; Ischemia Research and Education Foundation: Impact of preoperative anemia on outcome in patients undergoing coronary artery bypass graft surgery. Circulation 116: , Cladellas M, Bruguera J, Comín J, Vila J, de Jaime E, Martí J, Gomez M: Is pre-operative anaemia a risk marker for in-hospital mortality and morbidity after valve replacement? Eur Heart J 27: , Zindrou D, Taylor KM, Bagger JP: Preoperative haemoglobin concentration and mortality rate after coronary artery bypass surgery. Lancet 359: , Mancini DM, Katz SD, Lang CC, LaManca J, Hudaihed A, Androne AS: Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107: , Bolger AP, Bartlett FR, Penston HS, O Leary J, Pollock N, Kaprielian R, Chapman CM: Intravenous iron alone for the treatment of anemia in patients with chronic heart failure. JAm Coll Cardiol 48: , Silverberg DS, Wexler D, Blum M, Tchebiner JZ, Sheps D, Keren G, Schwartz D, Baruch R, Yachnin T, Shaked M, Schwartz I, Steinbruch S, Iaina A: The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol Dial Transplant 18: , Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 35: , Cladellas M, Farré N, Comín-Colet J, Gómez M, Mero~no O, Bosch MA, Vila J, Molera R, Segovia A, Bruguera J: Effects of preoperative intravenous erythropoietin plus iron on outcome in anemic patients after cardiac valve replacement. Am J Cardiol 110: , Unger EF, Thompson AM, Blank MJ, Temple R: Erythropoiesisstimulating agents time for a reevaluation. N Engl J Med 362: , Solomon SD, Uno H, Lewis EF, Eckardt KU, Lin J, Burdmann EA, de Zeeuw D, Ivanovich P, Levey AS, Parfrey P, Remuzzi G, Singh AK, Toto R, Huang F, Rossert J, McMurray JJ, Pfeffer MA; Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) Investigators: Erythropoietic response and outcomes in kidney disease and type 2 diabetes. NEnglJMed363: , Dunne JR, Malone D, Tracy JK, Gannon C, Napolitano LM: Perioperative anemia: An independent risk factor for infection, mortality, and resource utilization in surgery. JSurgRes102: , 2002 Received: January 23, 2014 Accepted: May 20, 2014 Published online ahead of print. Publication date available at www. cjasn.org.
Cardiovascular Surgery
Cardiovascular Surgery Preoperative Hemoglobin Level as a Predictor of Survival After Coronary Artery Bypass Grafting A Comparison With the Matched General Population Albert H.M. van Straten, MD; Mohamed
More informationErythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
ORIGINAL ARTICLE Nephrology http://dx.doi.org/1.3346/jkms.216.31.1.55 J Korean Med Sci 216; 31: 55- Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease Sun
More informationTrial to Reduce. Aranesp* Therapy. Cardiovascular Events with
Trial to Reduce Cardiovascular Events with Aranesp* Therapy John J.V. McMurray, Hajime Uno, Petr Jarolim, Akshay S. Desai, Dick de Zeeuw, Kai-Uwe Eckardt, Peter Ivanovich, Andrew S. Levey, Eldrin F. Lewis,
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationPreoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry after Cardiac Surgery
International Journal of ChemTech Research CODEN (USA): IJCRGG, ISSN: 0974-4290, ISSN(Online):2455-9555 Vol.11 No.06, pp 203-208, 2018 Preoperative Serum Bicarbonate Levels Predict Acute Kidney Iinjry
More informationErythropoiesis Stimulation and Heart Failure: Current Status
Erythropoiesis Stimulation and Heart Failure: Current Status Marc A. Pfeffer, MD, PhD Dzau Professor of Medicine, Harvard Medical School Cardiovascular Division, Brigham & Women s Hospital Boston, Massachusetts
More informationThe use of surrogates as key performance indicators
REPLY The use of surrogates as key performance indicators Dr José Vinhas Department of Nephrology, Centro Hospitalar de Setúbal. Setúbal, Portugal Received for publication: 24/08/2012 Accepted: 31/08/2012
More informationSubclinical changes in serum creatinine and mortality after coronary artery bypass grafting
Perioperative Management Tolpin et al Subclinical changes in serum creatinine and mortality after coronary artery bypass grafting Daniel A. Tolpin, MD, a,c Charles D. Collard, MD, a,c Vei-Vei Lee, MS,
More informationOn-Pump vs. Off-Pump CABG: The Controversy Continues. Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery
On-Pump vs. Off-Pump CABG: The Controversy Continues Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery On-pump vs. Off-Pump CABG: The Controversy Continues Conflict
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationS27. Aortic Valve Sparing Surgery in Marfan Syndrome Patients Raanani, Ehud 1 ; Hai, Ilan 2 ; Kuperstein, Refael 2 ; Nachum, Eyal-Ran
S27 Aortic Valve Sparing Surgery in Marfan Syndrome Patients Raanani, Ehud 1 ; Hai, Ilan 2 ; Kuperstein, Refael 2 ; Nachum, Eyal-Ran 1 ; Orlov, Boris 1 ; Malachy, Ateret 1 ; Shinfeld, Ami-Hai 1 1 Sheba
More informationAnemia in cardiac surgery: next target for mortality and morbidity improvement?
Original Article Anemia in cardiac surgery: next target for mortality and morbidity improvement? Asian Cardiovascular & Thoracic Annals 2016, Vol. 24(1) 12 17 ß The Author(s) 2015 Reprints and permissions:
More informationPreoperative Anemia versus Blood Transfusion: Which is the Culprit for Worse Outcomes in Cardiac Surgery?
Preoperative Anemia versus Blood Transfusion: Which is the Culprit for Worse Outcomes in Cardiac Surgery? Damien J. LaPar MD, MSc, James M. Isbell MD, MSCI, Jeffrey B. Rich MD, Alan M. Speir MD, Mohammed
More informationA Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery
A Novel Score to Estimate the Risk of Pneumonia After Cardiac Surgery Arman Kilic, MD 1, Rika Ohkuma, MD 1, J. Trent Magruder, MD 1, Joshua C. Grimm, MD 1, Marc Sussman, MD 1, Eric B. Schneider, PhD 1,
More informationTransfusion & Mortality. Philippe Van der Linden MD, PhD
Transfusion & Mortality Philippe Van der Linden MD, PhD Conflict of Interest Disclosure In the past 5 years, I have received honoraria or travel support for consulting or lecturing from the following companies:
More informationDoes Preoperative Hemoglobin Independently Predict Short-Term Outcomes After Coronary Artery Bypass Graft Surgery?
CARDIOTHORACIC ANESTHESIOLOGY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
More informationAnemia and mortality in patients with nondialysis-dependent chronic kidney disease
Stirnadel-Farrant et al. BMC Nephrology (2018) 19:135 https://doi.org/10.1186/s12882-018-0925-2 RESEARCH ARTICLE Open Access Anemia and mortality in patients with nondialysis-dependent chronic kidney disease
More informationAnemia Update. Target Hb TREAT study Functional iron deficiency - Hepcidin Biosimilar epoetins
Anemia Update Peter Bárány Department of Renal Medicine/ Karolinska University Hospital and Division of Renal Medicine Department of Clinical Science, Intervention and Technology Karolinska Institutet,
More informationIntraoperative application of Cytosorb in cardiac surgery
Intraoperative application of Cytosorb in cardiac surgery Dr. Carolyn Weber Heart Center of the University of Cologne Dept. of Cardiothoracic Surgery Cologne, Germany SIRS & Cardiopulmonary Bypass (CPB)
More informationEnd-Stage Renal Disease in the United States: An Update from the United States Renal Data System
End-Stage Renal Disease in the United States: An Update from the United States Renal Data System Robert N. Foley and Allan J. Collins United States Renal Data System Coordinating Center, Minneapolis, Minnesota
More informationSupplementary Online Content
1 Supplementary Online Content Friedman DJ, Piccini JP, Wang T, et al. Association between left atrial appendage occlusion and readmission for thromboembolism among patients with atrial fibrillation undergoing
More informationFigure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis).
Chronic Kidney Disease (CKD): The New Silent Killer Nelson Kopyt D.O. Chief of Nephrology, LVH Valley Kidney Specialists For the past several decades, the health care needs of Americans have shifted from
More informationENDPOINTS FOR AKI STUDIES
ENDPOINTS FOR AKI STUDIES Raymond Vanholder, University Hospital, Ghent, Belgium SUMMARY! AKI as an endpoint! Endpoints for studies in AKI 2 AKI AS AN ENDPOINT BEFORE RIFLE THE LIST OF DEFINITIONS WAS
More informationDoes the Use of Ultrafiltration Increase the Risk of Post-Operative Acute Kidney Injury? A Multi-Center Analysis
Does the Use of Ultrafiltration Increase the Risk of Post-Operative Acute Kidney Injury? A Multi-Center Analysis Gordon R. DeFoe, CCP, John Pieroni, CCP, Craig S. Warren, CCP, Charles F. Krumholz, CCP,
More informationSafety of Same-Day Coronary Angiography in Patients Undergoing Elective Aortic Valve Replacement
Safety of Same-Day Coronary Angiography in Patients Undergoing Elective Aortic Valve Replacement Kevin L. Greason, MD, Lars Englberger, MD, Rakesh M. Suri, MD, PhD, Soon J. Park, MD, Charanjit S. Rihal,
More information12 RANUCCI ET AL Ann Thorac Surg HEMODILUTION DURING CPB AND MORBIDITY RISK 2010;89:11 8 Abbreviations and Acronyms CI confidence interval CPB cardiop
ORIGINAL ARTICLES: CARDIOTHORACIC ANESTHESIOLOGY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must
More informationPrevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study
International Journal of Advances in Medicine Sathyan S et al. Int J Adv Med. 2017 Feb;4(1):247-251 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170120
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age
More informationStages of chronic kidney disease
For mass reproduction, content licensing and permissions contact Dowden Health Media. Jonathan J. Taliercio, DO Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio talierj@ccf.org
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationHMO: Medical (provider setting); Rx (out patient) PPO/CDHP: Rx
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Epogen, Procrit (epoetin alfa, injection) Commercial HMO/PPO/CDHP
More informationSurgical Consensus Standards Endorsement Maintenance NQF-Endorsed Surgical Maintenance Standards (Phase I) Table of Contents
Table of Contents #0113: Participation in a Systematic Database for Cardiac Surgery... 2 #0114: Post-operative Renal Failure... 2 #0115: Surgical Re-exploration... 3 #0116: Anti-Platelet Medication at
More informationAnemia is very common among end-stage renal fail LATEST STRATEGY IN RENAL ANEMIA MANAGEMENT IN PERITONEAL DIALYSIS PATIENTS.
Proceedings of the 3rd Asian Chapter Meeting of the ISPD November 22 24, 2007, Hiroshima, Japan Peritoneal Dialysis International, Vol. 28 (2008), Supplement 3 0896-8608/08 $3.00 +.00 Copyright 2008 International
More informationSESSION 5 2:20 3:35 pm
SESSION 2:2 3:3 pm Strategies to Reduce Cardiac Risk for Noncardiac Surgery SPEAKER Lee A. Fleisher, MD Presenter Disclosure Information The following relationships exist related to this presentation:
More informationSupplementary Online Content
Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter
More informationegfr > 50 (n = 13,916)
Saxagliptin and Cardiovascular Risk in Patients with Type 2 Diabetes Mellitus and Moderate or Severe Renal Impairment: Observations from the SAVOR-TIMI 53 Trial Supplementary Table 1. Characteristics according
More informationErythropoietin deficiency is an important contributor to
Nadir Levels after of Epoetin in Hemodialysis Patients Jose A. Calvo, Dana C. Miskulin, Klemens B. Meyer, and Daniel E. Weiner Tufts Medical Center and Tufts University School of Medicine, Boston, Massachusetts
More informationAcute Kidney Injury after Cardiac Surgery: Incidence, Risk Factors and Prevention
Acute Kidney Injury after Cardiac Surgery: Incidence, Risk Factors and Prevention Hong Liu, MD Professor of Clinical Anesthesiology Department of Anesthesiology and Pain Medicine University of California
More informationA Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD
A Validated Practical Risk Score to Predict the Need for RVAD after Continuous-flow LVAD SK Singh MD MSc, DK Pujara MBBS, J Anand MD, WE Cohn MD, OH Frazier MD, HR Mallidi MD Division of Transplant & Assist
More informationChapter 4: Cardiovascular Disease in Patients with CKD
Chapter 4: Cardiovascular Disease in Patients with CKD The prevalence of cardiovascular disease (CVD) was 65.8% among patients aged 66 and older who had chronic kidney disease (CKD), compared to 31.9%
More informationPeer Review Report. [erythropoietin-stimulating agents]
21 st Expert Committee on Selection and Use of Essential Medicines Peer Review Report [erythropoietin-stimulating agents] (1) Does the application adequately address the issue of the public health need
More informationModerators: Heather A. Nyman, Pharm.D., BCPS Clinical Pharmacist, Dialysis, University of Utah Dialysis Program, Salt Lake City, Utah
Immunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient Activity No. 0217-0000-11-076-L01-P (Knowledge-Based Activity) Monday, October 17 1:30
More informationPredicting Short Term Morbidity following Revision Hip and Knee Arthroplasty
Predicting Short Term Morbidity following Revision Hip and Knee Arthroplasty A Review of ACS-NSQIP 2006-2012 Arjun Sebastian, M.D., Stephanie Polites, M.D., Kristine Thomsen, B.S., Elizabeth Habermann,
More informationContrast Induced Nephropathy
Contrast Induced Nephropathy O CIAKI refers to an abrupt deterioration in renal function associated with the administration of iodinated contrast media O CIAKI is characterized by an acute (within 48 hours)
More informationAssessing Cardiac Risk in Noncardiac Surgery. Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington
Assessing Cardiac Risk in Noncardiac Surgery Murali Sivarajan, M.D. Professor University of Washington Seattle, Washington Disclosure None. I have no conflicts of interest, financial or otherwise. CME
More informationACS-NSQIP 2015 Julietta Chang MD, Ali Aminian MD, Stacy A Brethauer MD, Philip R Schauer MD Bariatric and Metabolic Institute
ACS-NSQIP 2015 Julietta Chang MD, Ali Aminian MD, Stacy A Brethauer MD, Philip R Schauer MD Bariatric and Metabolic Institute Disclosures Authors: No disclosures ACS-NSQIP Disclaimer: The American College
More informationConversion Dosing Guide:
Conversion Dosing Guide: From epoetin alfa to Aranesp in patients with anemia due to CKD on dialysis Indication Aranesp (darbepoetin alfa) is indicated for the treatment of anemia due to chronic kidney
More informationUniversity of Pennsylvania Health System Aprotinin Task Force
Aprotinin Use in Adult Cardiac Surgery: A Recommendation Statement from the University of Pennsylvania Health System Center for Evidence-based Practice *Note: This guideline was originally released on
More informationHigh-Risk Conventional Cardiac Surgery: Current Strategy. Disclosures: Edwards, Medtronic (Speaker)
High-Risk Conventional Cardiac Surgery: Current Strategy Disclosures: Edwards, Medtronic (Speaker) High-Risk Cardiac Surgery Considerations What defines high-risk? Strategies for preop optimization What
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationContemporary outcomes for surgical mitral valve repair: A benchmark for evaluating emerging mitral valve technology
Contemporary outcomes for surgical mitral valve repair: A benchmark for evaluating emerging mitral valve technology Damien J. LaPar, MD, MSc, Daniel P. Mulloy, MD, Ivan K. Crosby, MBBS, D. Scott Lim, MD,
More informationComparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics
Gilbertson et al. BMC Nephrology 2013, 14:44 RESEARCH ARTICLE Open Access Comparison of methodologies to define hemodialysis patients hyporesponsive to epoetin and impact on counts and characteristics
More informationGuidelines PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42. Prominent Dutch Cardiovascular Researcher Fired for Scientific Misconduct
PATHOLOGY: FATAL PERIOPERATIVE MI NON-PMI N = 25 PMI N = 42 Preoperative, Intraoperative, and Postoperative Factors Associated with Perioperative Cardiac Complications in Patients Undergoing Major Noncardiac
More informationIs preoperative serum creatinine a reliable indicator of outcome in patients undergoing coronary artery bypass surgery?
Is preoperative serum creatinine a reliable indicator of outcome in patients undergoing coronary artery bypass surgery? Mahdi Najafi, MD, a Hamidreza Goodarzynejad, MD, c Abbasali Karimi, MD, b Abbas Ghiasi,
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 2: Identification and Care of Patients With CKD Over half of patients from the Medicare 5 percent sample have either a diagnosis of chronic kidney disease
More informationCABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin
CABG in the Post-Aprotinin Era: Are We Doing Better? Ziv Beckerman, David Kadosh, Zvi Peled, Keren Bitton-Worms, Oved Cohen and Gil Bolotin DISCLOSURES None Objective(s): Our department routinely used
More informationOutcomes of off-pump versus on-pump coronary artery bypass grafting: Impact of preoperative risk
ACQUIRED CARDIOVASCULAR DISEASE Outcomes of off-pump versus on-pump coronary artery bypass grafting: Impact of preoperative risk Marek Polomsky, MD, a Xia He, MS, b Sean M. O Brien, PhD, b and John D.
More informationImmunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient
Immunology/Transplantation and Nephrology PRNs Focus Session Long-term Management of the Renal Transplant Recipient Activity No. 0217-0000-11-076-L01-P Monday, October 17 1:30 p.m. 3:30 p.m. Convention
More informationBecause of important technologic advances achieved over
Anemia and Heart Failure in Chronic Kidney Disease Francesco Locatelli, Pietro Pozzoni, and Lucia Del Vecchio Cardiovascular disease is mainly responsible for the poor long-term survival observed in chronic
More informationChapter 9: Cardiovascular Disease in Patients With ESRD
Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in adult ESRD patients, with atherosclerotic heart disease and congestive heart failure being the most common conditions
More informationDoes preoperative atrial fibrillation increase the risk for mortality and morbidity after coronary artery bypass grafting?
Ad et al Acquired Cardiovascular Disease Does preoperative atrial fibrillation increase the risk for mortality and morbidity after coronary artery bypass grafting? Niv Ad, MD, a Scott D. Barnett, PhD,
More informationAnalysis of Mortality Within the First Six Months After Coronary Reoperation
Analysis of Mortality Within the First Six Months After Coronary Reoperation Frans M. van Eck, MD, Luc Noyez, MD, PhD, Freek W. A. Verheugt, MD, PhD, and Rene M. H. J. Brouwer, MD, PhD Departments of Thoracic
More informationPrediction of acute renal failure after cardiac surgery: retrospective cross-validation of a clinical algorithm
Nephrol Dial Transplant (2003) 18: 77 81 Original Article Prediction of acute renal failure after cardiac surgery: retrospective cross-validation of a clinical algorithm Bjørn O. Eriksen 1, Kristel R.
More informationManaging Hypertension in the Perioperative Arena
Managing Hypertension in the Perioperative Arena Optimizing Perioperative Management Strategies for Hypertension in the Cardiac Surgical Patient Objectives: Treatment of hypertensive emergencies. ALBERT
More informationObservational studies have shown a strong detrimental
Association of Fluid Retention With Anemia and Clinical Outcomes Among Patients With Chronic Kidney Disease Szu-Chun Hung, MD; Ko-Lin Kuo, MD, PhD; Ching-Hsiu Peng, MD; Che-Hsiung Wu, MD; Yi-Chun Wang,
More informationSYNOPSIS. Issue Date: 04 February 2009 Document No.: EDMS -USRA
SYNOPSIS Issue Date: 04 February 2009 Document No.: EDMS -USRA-10751204 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Johnson & Johnson Pharmaceutical Research & Development,
More informationPrevalence of Anemia and Renal Insufficiency in Non-Hospitalized Patients with Heart Failure
Prevalence of Anemia and Renal Insufficiency in Non-Hospitalized Patients with Heart Failure Francisco José Farias Borges dos Reis, André Maurício Souza Fernandes, Almir Galvão Vieira Bitencourt, Flávia
More informationEACTS Adult Cardiac Database
EACTS Adult Cardiac Database Quality Improvement Programme List of changes to Version 2.0, 13 th Dec 2018, compared to version 1.0, 1 st May 2014. INTRODUCTORY NOTES This document s purpose is to list
More informationALLHAT RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR)
1 RENAL DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED INTO 4 GROUPS BY BASELINE GLOMERULAR FILTRATION RATE (GFR) 6 / 5 / 1006-1 2 Introduction Hypertension is the second most common cause of end-stage
More informationTAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:
TAVR in patients with End-Stage CKD or in Renal Replacement Therapy: Special Considerations and Prevention of early Valve Failure Antonios Chalapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens,
More informationCardiac disease is well known to be the leading cause
Coronary Artery Bypass Grafting in Who Require Long-Term Dialysis Leena Khaitan, MD, Francis P. Sutter, DO, and Scott M. Goldman, MD Main Line Cardiothoracic Surgeons, Lankenau Hospital, Jefferson Health
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationEdgar Hernández-Leiva 1*, Rodolfo Dennis 2, Daniel Isaza 3 and Juan Pablo Umaña 4
Hernández-Leiva et al. Journal of Cardiothoracic Surgery 2013, 8:170 RESEARCH ARTICLE Open Access Hemoglobin and B-type natriuretic peptide preoperative values but not inflammatory markers, are associated
More informationPatients with chronic kidney disease (CKD) are
CLINICAL INTERVENTIONS TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH KIDNEY DISEASE Jeffrey S. Berns, MD* ABSTRACT Although the specific mechanisms by which chronic kidney disease (CKD) and cardiovascular
More informationConcept and General Objectives of the Conference: Prognosis Matters. Andrew S. Levey, MD Tufts Medical Center Boston, MA
Concept and General Objectives of the Conference: Prognosis Matters Andrew S. Levey, MD Tufts Medical Center Boston, MA General Objectives Topics to discuss What are the key outcomes of CKD? What progress
More informationPreoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD
Preoperative anemia Common, consequential and correctable in non-emergent surgery By Kathrine Frey, MD Preoperative anemia is common, especially in patients undergoing nonemergent high-blood-loss surgical
More informationCRAIOVA UNIVERSITY OF MEDICINE AND PHARMACY FACULTY OF MEDICINE ABSTRACT DOCTORAL THESIS
CRAIOVA UNIVERSITY OF MEDICINE AND PHARMACY FACULTY OF MEDICINE ABSTRACT DOCTORAL THESIS RISK FACTORS IN THE EMERGENCE OF POSTOPERATIVE RENAL FAILURE, IMPACT OF TREATMENT WITH ACE INHIBITORS Scientific
More informationMulticenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) Long Term Outcomes
Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with (MOMENTUM 3) Long Term Outcomes Mandeep R. Mehra, MD, Daniel J. Goldstein, MD, Nir Uriel, MD, Joseph
More informationCurrent situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationOutcomes of Surgical Aortic Valve Replacement in Moderate Risk Patients: Implications for Determination of Equipoise in the Transcatheter Era
Outcomes of Surgical Aortic Valve Replacement in Moderate Risk Patients: Implications for Determination of Equipoise in the Transcatheter Era Sebastian A. Iturra, Rakesh M. Suri, Kevin L. Greason, John
More informationAssociation of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients
Kidney International, Vol. 65 (2004), pp. 626 633 Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients SUYING LI and ALLAN J. COLLINS Nephrology
More informationRisk Factors and Management of Acute Renal Injury in Cardiac Surgery
Risk Factors and Management of Acute Renal Injury in Cardiac Surgery Robert S Kramer, MD, FACS Clinical Associate Professor of Surgery Tufts University School of Medicine Maine Medical Center, Portland
More informationEffects of Kidney Disease on Cardiovascular Morbidity and Mortality
Effects of Kidney Disease on Cardiovascular Morbidity and Mortality Joachim H. Ix, MD, MAS Assistant Professor in Residence Division of Nephrology University of California San Diego, and Veterans Affairs
More informationª 2014 by the American College of Surgeons ISSN /13/$
Effect of Preoperative Renal Insufficiency on Postoperative Outcomes after Pancreatic Resection: A Single Institution Experience of 1,061 Consecutive Patients Malcolm H Squires III, MD, MS, Vishes V Mehta,
More informationComment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.
Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
More informationThe Author(s) This article is published with open access by ASEAN Federation of Cardiology
DOI 10.7603/s40602-014-0011-3 ASEAN Heart Journal http://www.aseanheartjournal.org/ Vol. 22, no. 1, 60 65 (2014) ISSN: 2315-4551 Erratum Erratum to: Impact Of Sex On Clinical Characteristics And In-Hospital
More informationEvidence-based practice in nephrology : Meta-analysis
Evidence-based practice in nephrology : Meta-analysis Paweena Susantitaphong, MD,Ph.D 1-3 1 Associate Professor, Division of Nephrology, Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn
More informationIN the setting of cardiac surgery, postoperative acute kidney
Platelet Counts, Acute Kidney Injury, and Mortality after Coronary Artery Bypass Grafting Surgery Miklos D. Kertai, M.D., Ph.D., Shan Zhou, M.D., Jörn A. Karhausen, M.D., Mary Cooter, M.Sc., Edmund Jooste,
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More information8/28/2018. Pre-op Evaluation for non cardiac surgery. A quick review from 2007!! Disclosures. John Steuter, MD. None
Pre-op Evaluation for non cardiac surgery John Steuter, MD Disclosures None A quick review from 2007!! Fliesheret al, ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and are for Noncardiac
More informationFEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery
EUROPEAN SOCIETY OF CARDIOLOGY CONGRESS 2010 FEV1 predicts length of stay and in-hospital mortality in patients undergoing cardiac surgery Nicholas L Mills, David A McAllister, Sarah Wild, John D MacLay,
More informationInstitute of Medical Epidemiology, Biostatistics, and Informatics, University of Halle-Wittenberg, Halle (Saale) 2
Do Randomized and Non-Randomized Trials Yield Different Answers in Similar Populations? Evidence from a 'Meta-Propensity Score' Analysis in Cardiac Surgery Kuss O 1, Legler T 1, Börgermann J 2 1 Institute
More informationChairman and O. Wayne Isom Professor Department of Cardiothoracic Surgery Weill Cornell Medicine
Leonard N. Girardi, M.D. Chairman and O. Wayne Isom Professor Department of Cardiothoracic Surgery Weill Cornell Medicine New York, New York Houston Aortic Symposium Houston, Texas February 23, 2017 weill.cornell.edu
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 9: Cardiovascular Disease in Patients With ESRD Cardiovascular disease is common in ESRD patients, with atherosclerotic heart disease and congestive heart
More informationThe role of correction of anaemia in patients with congestive heart failure: A short review
European Journal of Heart Failure 10 (2008) 819 823 www.elsevier.com/locate/ejheart Review The role of correction of anaemia in patients with congestive heart failure: A short review Donald S. Silverberg
More informationHome Hemodialysis or Transplantation of the Treatment of Choice for Elderly?
Home Hemodialysis or Transplantation of the Treatment of Choice for Elderly? Miklos Z Molnar, MD, PhD, FEBTM, FERA, FASN Associate Professor of Medicine Division of Nephrology, Department of Medicine University
More informationAnemia response to Methoxy
Open Access Journal of Clinical Nephrology Research Article Anemia response to Methoxy ISSN 2576-9529 Polyethylene Glycol-Epoetin Beta (Mircera) versus Epoetin Alfa (Eprex) in patients with chronic Kidney
More information